CWA Asset Management Group LLC Acquires 5,017 Shares of Organon & Co. (NYSE:OGN)

CWA Asset Management Group LLC increased its holdings in Organon & Co. (NYSE:OGN) by 27.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,596 shares of the company’s stock after buying an additional 5,017 shares during the period. CWA Asset Management Group LLC’s holdings in Organon & Co. were worth $352,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after purchasing an additional 82,220 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Organon & Co. by 39.8% in the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock valued at $71,905,000 after purchasing an additional 988,336 shares during the period. Deprince Race & Zollo Inc. grew its position in shares of Organon & Co. by 6.8% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock valued at $70,829,000 after purchasing an additional 216,907 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock worth $63,570,000 after purchasing an additional 875,128 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Organon & Co. by 23.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock worth $49,843,000 after buying an additional 463,216 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Price Performance

OGN stock opened at $15.99 on Thursday. The firm has a 50 day simple moving average of $15.46 and a two-hundred day simple moving average of $18.46. The stock has a market cap of $4.12 billion, a PE ratio of 3.17, a P/E/G ratio of 0.81 and a beta of 0.76. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.78 earnings per share. On average, analysts predict that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.00%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.